

IN THE UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF WASHINGTON
AT SPOKANE

BEAU ARMSTRONG,

Plaintiff,

v.

ATRIUM MEDICAL CORPORATION; GETINGE
AB; MAQUET CARDIOVASCULAR US SALES,
LLC;

Defendants.

NO.

COMPLAINT AND DEMAND FOR JURY TRIAL

Plaintiff Beau Armstrong, by and through his undersigned counsel, alleges as follows:

INTRODUCTION

1. This case involves a synthetic mesh medical device, known as ProLite polypropylene mesh ("ProLite"), manufactured, promoted, marketed, distributed and sold by Defendants for use in hernia repair.

2. The ProLite mesh is a non-absorbable surgical mesh constructed of monofilaments of polypropylene.

3. Defendants misrepresented that ProLite is a safe and effective medical device for hernia repair. In fact, ProLite causes a litany of serious medical problems and complications, including, but not limited to, mesh shrinkage, deformation, material degradation, foreign body

1 reaction, chronic inflammation, mesh infection, migration, organ damage, nerve damage, chronic
2 pain and sexual dysfunction.

3 4. Plaintiff brings this action to recover damages for injuries resulting from the strict
4 liability, failure to warn, negligence, negligent misrepresentation, and breach of implied and
5 express warranties by Defendants in the manufacture, promotion, marketing, distribution and sale
6 of ProLite polypropylene mesh.

7 **PARTIES**

8 1. Plaintiff Beau Armstrong ("Plaintiff") is a resident of the State of Washington.

9 2. Defendant Getinge AB ("Getinge") is a Swedish corporation doing business in the
10 United States. Getinge is a pharmaceutical company involved in the research, development,
11 testing, manufacture, production, distribution, marketing, promotion and/or sale of medical
12 devices used for hernia repair, including ProLite polypropylene mesh.

13 3. Defendant Atrium Medical Corporation ("Atrium") is a Delaware corporation
14 headquartered in New Hampshire. Atrium is a wholly-owned subsidiary of Getinge. Atrium is a
15 medical device company involved in the research, development, testing, manufacture,
16 production, distribution, marketing, promotion and/or sale of medical devices used for hernia
17 repair, including – at all times relevant hereto – ProLite polypropylene mesh. In 2011, Atrium was
18 acquired by Getinge in a transaction which involved, *inter alia*, the transfer of all Atrium's liquid
19 assets to Getinge and the effective dissolution of Atrium's board of directors. After being
20 acquired by Getinge, Atrium ceased to file annual reports with the State of New Hampshire,
21 causing its authority to transact business therein to be suspended. Getinge thereupon applied for
22 requalification to conduct business in New Hampshire using Atrium's corporate name. Following
23 Getinge's acquisition of Atrium, Getinge controls the activities of Atrium and is the direct
24 employer of the individuals formerly employed by Atrium.

25 4. Defendant Maquet Cardiovascular US Sales, LLC ("Maquet Cardiovascular") is a
26 Delaware corporation headquartered at 45 Barbour Pond Drive, Wayne, New Jersey. Maquet
Cardiovascular is a pharmaceutical company involved in the research, development, testing,

DIAMONDMASSONG, PLLC
1215 Fourth Avenue, Suite 1275
Seattle, WA 98161
206.445.1258 Phone • 206.445.1257 Fax

1 manufacture, production, distribution, marketing, promotion and/or sale of medical devices used
2 for hernia repair, including – at all times relevant hereto – ProLite polypropylene mesh. Maquet is
3 a wholly owned subsidiary of Getinge and is the exclusive distributor of all surgical mesh products
4 manufactured by Defendants. Maquet Cardiovascular has four members:

- 5 a. Stephanie Trizinski, a citizen of the State of New Jersey;
- 6 b. Jennifer Paradise, a citizen of the State of New Jersey;
- 7 c. John McPartlin, a citizen of the State of New Jersey; and
- 8 d. Datascope Corp., a Delaware corporation headquartered in New Jersey.

9 **JURISDICTION AND VENUE**

10 1. This Court has subject matter jurisdiction over this action pursuant to 28 U.S.C.
11 section 1332. Plaintiff is a citizen of a state different from Defendants and the amount in
12 controversy, exclusive of interest and costs, exceeds \$75,000.

13 2. This Court has personal jurisdiction over each defendant because each Defendant
14 purposefully directed its marketing, sales and distribution of numerous pharmaceutical and/or
15 healthcare products to Washington. Each Defendant has substantial contacts with Washington
16 such that maintenance of this action is consistent with traditional notions of fair play and
17 substantial justice.

18 3. Venue is proper in this Court pursuant to 28 U.S.C. section 1391(b). Each Defendant
19 is a resident of this district, does business in this district, is subject to personal jurisdiction in this
20 district, and a substantial part of the events giving rise to the claims set forth in this Complaint
21 occurred in this district.

22 **FACTUAL BACKGROUND**

23 **POLYPROPYLENE MESH**

24 1. Hernia, a condition affecting thousands of men and women in the United States
25 each year, is the protrusion or projection of an organ or tissue through the wall that normally
26 contains it. Although a hernia may form in any part of the abdominal wall, the most common site

1 is the groin. Groin hernias are known as inguinal or femoral, depending on the location of the
2 hernia.

3 2. Until 1958, abdominal wall hernias were repaired without mesh. In 1958, Dr.
4 Frances Usher published a medical journal article entitled *Marlex mesh, a new plastic mesh for*
5 *replacing tissue defects*. Dr. Usher used polypropylene mesh in experimental canine work for
6 abdominal repair. Polypropylene is a petroleum-based plastic initially used in the Hula-Hoop and
7 for kitchen storage applications.

8 3. Heavily promoted by the medical device manufacturers, including Defendants,
9 hernia mesh, typically made wholly or partly of polypropylene, is commonly used in hernia repair
10 surgery.

11 4. It has been known since 1953 that any implanted device must not be physically
12 modified by tissue fluids, be chemically inert, not incite an inflammatory or foreign body cell
13 reaction, be non-carcinogenic, not produce allergic reactions, and be able to withstand mechanical
14 stress. D. Ostergard, *Degradation, Infection and Heat Effects on Polypropylene Mesh for Pelvic*
15 *Implantation: What Was Known and When it Was Known*, 22 INT'L UROGYNECOLOGY J. 771-774
16 (2011).

17 5. Polypropylene is not biologically inert in the human body, and can cause serious
18 injury to patients, significantly impacting their quality of life. As one author stated, "[p]rosthetic
19 meshes are ... not the inert materials they are claimed to be and can expand as well as shrink." A.
20 Coda, *Structural Alterations of Prosthetic Meshes in Humans*, 7 HERNIA 29-34 (2003).

21 6. A typical response to mesh implanted in the human body is inflammation,
22 granuloma formation and a foreign body reaction. Scar tissue forms around the implant and
23 causes contraction of the mesh up to 50%. This inflammation, foreign body response and scar
24 tissue formation is a permanent condition and can result in long-term complications. U. Klinge et
25 al., *Foreign Body Reaction to Meshes Used for the Repair of Abdominal Wall Hernias*, 165 EUR. J.
26 SURGERY 665-73 (1999).

1 7. Despite the promotion of mesh as safe and effective by Defendants, the published
2 medical literature contradicts this unsupported belief. One author observed that “[t]he literature
3 suggests otherwise with reports of various degrees of degradation, including depolymerization,
4 cross-linking, oxidative degradation by free radicals, additive leaching, hydrolysis, stress cracking
5 and mesh shrinkage along with infection, chronic inflammation and the stimulation of sclerosis.”
6 The author concluded, “Based on available evidence the polypropylene used for surgical
7 treatment of various structural defects is not inert after implantation in the human body.” G.
8 Sternschuss et al., *Postimplantation Alterations of Polypropylene in the Human*, 188 J. UROL. 27-
9 32 (2012). As the mesh degrades in the human body, small flakes of polypropylene can lead to
10 infection and irritation, and resultant serious pain, as the body tries to rid itself of the foreign
11 material.

12 8. Once implanted, mesh contracts as well as cracks substantially in the human body.
13 In one study, a contracture rate of 30% to 50% was found four weeks after implantation. Another
14 study reported an 85% contracture rate after eight years. Nerve fibers are entrapped in the
15 contracted tissue causing severe pain.

16 9. A debilitating consequence of hernia repair with mesh is inguinodynia, or chronic
17 groin pain. This condition results from nerves, such as the ilioinguinal, iliohypogastric and
18 genitofemoral nerves, coming into contact with mesh, after its degradation and deformation in
19 the body following implantation, and from the persistent and permanent foreign body reaction
20 to the implantation of mesh. It has been reported that hernia repair with mesh results in an
21 extraordinarily high rate of inguinodynia – in some reports approaching 50%. *See, e.g., J.E.*
22 *Fischer, Hernia Repair: Why Do We Continue to Perform Mesh Repair in the Face of Human Toll*
23 *of Inguinodynia?* 206 AMER. J. SURG. 619-23 (2013).

24 10. Other studies have found an even higher rate of chronic pain after hernia repair
25 with mesh. One study found that approximately 75% of patients had pain one year after hernia
26 repair at rest, and 78% had pain when moving. B. Page, *Pain from Primary Inguinal Hernia and*
the Effect of Repair on Pain, 89 BRIT. J. SURG. 1315-18 (2002).

DEFENDANTS' PROLITE MESH

1
2 1. On December 16, 1993, Atrium received notification from the FDA that the 510(k)
3 submission for Atrium Polypropylene Monofilament Mesh had been approved, finding the device
4 to be substantially equivalent to a pre-MDA device or another device which had been granted
5 clearance under 510(k). The granted clearance (K930669) applied to the product the
6 specifications of which had been transmitted to the FDA for review, namely a flat, low-profile
7 polypropylene monofilament surgical mesh which was later commercialized under the trade
8 name ProLite.

9 2. Around 2003, Atrium was notified by its polypropylene supplier that it would no
10 longer be supplying polypropylene to customers using the polymer for applications involving
11 permanent human implantation.

12 3. Thereupon, Atrium began evaluating replacement polypropylene resins by
13 conducting a variety of tests on candidate polypropylene samples.

14 4. Among the polymers nominated to replace the polypropylene Atrium used at the
15 time the ProLite was cleared by the FDA was a resin called Profax-6523 manufactured by a Dutch
16 company called LyondellBasell.

17 5. Of all of the samples which Atrium tested, Profax-6523 was the only polypropylene
18 resin which did not contain any antioxidant additives.

19 6. In 2005, Atrium issued an Engineering Change Order to begin manufacturing ProLite
20 using Profax-6523 despite the fact that it lacked antioxidants and despite LyondellBasell's
21 admonition that Profax-6523 was not approved for applications involving permanent human
22 implantation.

23 7. Atrium made this significant change to the base material of the ProLite without
24 obtaining supplementary clearance pursuant to Section 510(k) of the Food Drug and Cosmetic Act
25 (FDCA), making the ProLite misbranded pursuant to 21 U.S.C. 352(o) and adulterated pursuant to
26 21 U.S.C. 351(f)(1)(B).

1 8. While it is typical for polypropylene used in medical applications to contain anti-
2 oxidant additives to prevent oxidative degradation *in vivo*, ProLite's construction from Profax-6523,
3 which completely lacks such anti-oxidants, makes it unreasonably susceptible to oxidative
4 degradation.

5 9. Atrium was aware that its chosen polypropylene lacked antioxidants when it
6 elected to move forward manufacturing ProLite with said polypropylene formulation.

7 10. Atrium performed tests demonstrating that such polypropylene formulation
8 oxidized and degraded faster than polypropylene which had been stabilized with antioxidant
9 additives.

10 11. Degraded polypropylene substantially raises the risk of infection, chronic pain, mesh
11 contracture, meshoma, and mesh migration.

12 12. The ProLite contains a number of design elements which render the product
13 unreasonably dangerous to the patient, including but not limited to the following:

- 14 a. The heavyweight, small-pore construction of ProLite results in a high volume of
15 non-asorbable synthetic polypropylene material in the patient's soft tissue,
16 increasing the magnitude of the host inflammatory response and – as a result –
17 the risk of chronic pain, the risk and rate of harmful polypropylene degradation,
18 and mesh contracture; and
19 b. The unstabilized polypropylene base material results in a drastically increased
20 risk of infection, mesh erosion, chronic pain, excessive scarring, contracture,
21 and meshoma as a result of *in vivo* degradation.

22 13. Despite the abundance of scientific and medical information published in the
23 literature relating to the dangerous properties and serious risks of polypropylene mesh,
24 Defendants made a deliberate decision to ignore these dangers and to aggressively promote
25 ProLite polypropylene mesh to healthcare providers and consumers. Defendants misrepresented
26 and concealed from Plaintiff, Plaintiff's physicians and consumers, the serious risks, dangers and
defects enumerated in this Complaint.

PLAINTIFF FACTUAL ALLEGATIONS

1
2
3
4 1. Plaintiff Beau Armstrong was 41 years old when he underwent parastomal hernia
5 repair surgery by Dr. Kevin Robertson on January 12, 2018 at Providence St. Peter Hospital in
6 Olympia, Washington. During the procedure, Plaintiff's surgeon implanted a ProLite mesh,
7 Catalog number 1000306-00; Lot number 418997. The mesh was implanted in a manner
8 consistent with Defendants' Instructions for Use and in a manner reasonably foreseeable to
9 Defendants. Years after such implantation, Plaintiff suffered a hernia recurrence and the onset
10 of severe groin pain. Plaintiff underwent surgery on June 12, 2020 in which it was discovered
11 that the ProLite mesh had eroded into Plaintiff's bowel and caused a peristomal abscess which
12 had fistulized to the skin. Plaintiff's surgeons had to perform a complex revision of the ileal
13 conduit, mesh excision, and incisional hernia repair.

14 2. The hernia mesh implanted in Plaintiff by his surgeon was ProLite polypropylene
15 mesh manufactured, promoted, marketed, distributed and sold by Defendants.

16 3. The ProLite polypropylene mesh caused Plaintiff to suffer permanent injuries,
17 substantial pain and suffering, emotional distress, medical expenses, lost wages and earning
18 capacity, and diminished quality of life.

19 4. Before Plaintiff underwent hernia repair surgery with ProLite polypropylene mesh,
20 he had no history of these physical and emotional injuries.

21 5. Plaintiff files this lawsuit within the applicable limitations period of first suspecting
22 that ProLite polypropylene mesh caused the harm and injuries suffered by Plaintiff. Plaintiff
23 could not, by the exercise of reasonable diligence, have discovered the wrongful cause of his
24 injuries at an earlier time because the injuries were caused without perceptible trauma or harm,
25 and when the injuries were discovered, their cause was unknown to Plaintiff. Plaintiff did not
26 suspect, nor did Plaintiff have reason to suspect, that he had been injured, the cause of the
injuries, or the wrongful nature of the conduct causing the injuries, until less than the applicable

1 limitations period before the filing of this complaint. Moreover, Plaintiff was prevented from
2 discovering this information sooner because Defendants misrepresented and concealed, and
3 continue to misrepresent and conceal to the public and the medical profession, the dangers of
4 ProLite polypropylene mesh, as well as the true facts that could have led Plaintiff to discover a
5 cause of action against Defendants for their wrongful conduct.

6 **CLAIMS PURSUANT TO THE WASHINGTON PRODUCT LIABILITY ACT**

7 Pursuant to the Washington Product Liability Act, Chapter 7.72 RCW (the "WPLA"),
8 Plaintiff brings the following claims:

9 1. It was entirely foreseeable and well-known to Defendants that incidents involving
10 its ProLite mesh such as occurred herein would on occasion take place in the ordinary,
11 anticipated and intended use of said devices.

12 2. Defendants defectively designed, manufactured, assembled and marketed the
13 ProLite mesh in question and so are strictly liable for Plaintiff's damages.

14 3. The ProLite mesh is defective because Defendants failed to provide adequate
15 warnings and/or instructions regarding the defective conditions and/or the proper use of the
16 device and so are strictly liable for Plaintiff's damages.

17 4. Defendants breached the implied warranties of merchantability and fitness for a
18 particular purpose, and so are liable for Plaintiff's damages.

19 5. Defendants were negligent in the design, manufacture, assembly and marketing
20 of the ProLite mesh in question and so are strictly liable for Plaintiff's damages.

21 6. Plaintiff's surgeon, Dr. Robinson, used the ProLite mesh as directed for its
22 intended purpose.

23 7. At all times herein mentioned, the ProLite mesh used on Plaintiff was defective
24 within the meaning of the WPLA, and Defendants knew of the product defects.
25
26

1 8. Moreover, Defendants knew neither Plaintiff nor his surgeon knew or had reason
2 to know of the product defects. Neither Plaintiff nor his surgeon could have discovered the
3 product defects through the exercise of reasonable care and diligent inquiry.

4 9. The ProLite mesh had not been materially altered or modified prior to being
5 used on Plaintiff.

6 10. At all times material, Defendants were acting through their employees and/or
7 agents who were within the course and scope of their employment and/or agency for one or
8 all of the Defendants. The Defendants are therefore equally liable under the doctrine of
9 *Respondeat Superior* and/or principles of agency for all actions of their employees and/or
10 agents.

11 11. Defendants' acts and/or omissions were, separately and collectively with the acts
12 and omissions of other Defendants named herein, a producing and/or proximate cause of Plaintiffs
13 damages.

14 **PUNITIVE DAMAGES ALLEGATIONS**

15 Plaintiff incorporates by reference herein all of the allegations in this Complaint as if fully
16 set forth herein.

17 1. The acts, conduct and concealment of Defendants, as alleged in this Complaint,
18 were willful, malicious, oppressive and fraudulent. Defendants committed these acts with a
19 conscious disregard for the rights and safety of Plaintiff and other consumers, and for the primary
20 purpose of increasing Defendants' profits from the distribution and sale of ProLite polypropylene
21 mesh. Defendants' outrageous and unconscionable conduct warrants the imposition of punitive
22 damages against Defendants in an amount appropriate to punish and deter such conduct in the
23 future.

24 2. Before the manufacture, promotion, distribution and sale of ProLite polypropylene
25 mesh to Plaintiff, Defendants knew that it was in a defective condition, and knew that they had
26 made a strategic decision to fraudulently represent and intentionally conceal the significant risks
and serious dangers of ProLite polypropylene mesh, as described in this Complaint, and knew that

1 consumers who used ProLite polypropylene mesh for hernia repair would, and did, experience
 2 severe physical, mental and emotional injuries. Further, Defendants, through their officers,
 3 directors, managers and agents, knew that ProLite polypropylene mesh presented a substantial
 4 and unreasonable risk of harm to the public, including Plaintiff. Thus, Defendants unreasonably,
 5 maliciously, oppressively and fraudulently subjected consumers of ProLite polypropylene mesh,
 6 including Plaintiff, to the risk of serious injury.

7 3. Despite their knowledge, Defendants, acting through their officers, directors and
 8 managing agents for the purpose of enhancing the profits of Defendants, knowingly and
 9 deliberately failed to remedy the known defects in ProLite polypropylene mesh and failed to warn
 10 the public, including Plaintiff, of the serious risk of injury caused by the defects in ProLite
 11 polypropylene mesh. Defendants and their officers, directors and managing agents, intentionally
 12 proceeded with the manufacture, sale, distribution and marketing of ProLite polypropylene mesh
 13 knowing these actions would expose consumers, including Plaintiff, to serious danger in order to
 14 advance Defendants' financial interests and increase revenue.

15 4. Defendants' conduct was despicable and so contemptible that it would be looked
 16 down upon and despised by ordinary decent people and was carried on by Defendants with
 17 willful and conscious disregard for the rights and safety of Plaintiff and other consumers,
 18 thereby entitling Plaintiff to the imposition of punitive damages.

19 **WHEREFORE**, Plaintiff prays for judgment against Defendants, as follows:

- 20 1. General damages, according to proof;
- 21 2. Special damages, according to proof;
- 22 3. Loss of earnings and earning capacity, according to proof;
- 23 4. Medical expenses, past and future, according to proof;
- 24 5. Mental and emotional distress, past and future, according to proof;
- 25 6. Punitive damages, according to proof;
- 26 7. Costs of suit herein;
8. Pre-judgment and post-judgment interest, as provided by law; and

1 9. Such other and further relief as the Court may deem just and proper.

2 **DEMAND FOR JURY TRIAL**

3 Plaintiff hereby demands a trial by jury on all counts and as to all issues.

4
5 Respectfully submitted this 12th day of January, 2022

6
7 **DIAMOND MASSONG, PLLC**

8 By: 

9 Maria S. Diamond, WSBA No. 13472

10 1215 Fourth Avenue, Suite 1275

11 Seattle Washington 98161

12 (206) 445-1258

13 Facsimile: (206) 445-1257

14 maria@diamondmassong.com

15 Attorney for Plaintiff